Src Family Kinase Inhibitors Bosutinib and Dasatinib Enhance ATRA-induced Differentiation of NB4 Leukemia Cells
Anticancer Research · 2026-07 · 46 (7) · 3831-3844
DOI: 10.21873/anticanres.18244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, online erschienen am 29.06.2026. Verfasst von Min-Young Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Aniline Compounds, Tretinoin, Dasatinib, Quinolines.
Abstract (Originalsprache)
BACKGROUND/AIM: Acute promyelocytic leukemia (APL) has been treated for decades with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO), which achieve excellent survival but remain limited by induction mortality, ATO-related toxicities, and relapse in some patients. Src family kinases (SFKs) regulate proliferation and survival of myeloid lineage cells, and SFK inhibition has been reported to enhance retinoic acid (RA)-induced differentiation. We investigated whether clinically available SFK inhibitors can augment ATRA-induced differentiation of APL-derived NB4 cells more effectively than the ATRA plus ATO standard regimen. MATERIALS AND METHODS: NB4 cells were treated with PP2, bosutinib, or dasatinib with or without ATRA. Differentiation was assessed by CD11b expression using flow cytometry and by nitroblue tetrazolium reduction. SFK phosphorylation and retinoic acid receptor (RAR) target gene expression were evaluated by immunoblotting. Apoptosis was analyzed to distinguish differentiation from cytotoxic effects. RESULTS:
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea.
- Institute for Clinical Molecular Biology Research, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea.
- Department of Laboratory Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea.
- Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea.
- Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea; jhwon@schmc.ac.kr.
Zitieren
APA
Lee, M. Y., Cheong, H. J., Yoon, S. Y., Kim, K. H., Lee, N., Park, R., Park, S. K., & Won, J. H. (2026). Src Family Kinase Inhibitors Bosutinib and Dasatinib Enhance ATRA-induced Differentiation of NB4 Leukemia Cells. Anticancer Research, 46(7), 3831-3844. https://doi.org/10.21873/anticanres.18244
Vancouver
Lee MY, Cheong HJ, Yoon SY, Kim KH, Lee N, Park R, et al. Src Family Kinase Inhibitors Bosutinib and Dasatinib Enhance ATRA-induced Differentiation of NB4 Leukemia Cells. Anticancer Research. 2026;46(7):3831-3844. doi:10.21873/anticanres.18244
BibTeX
@article{Lee2026,
author = {Lee, Min-Young and Cheong, Hee-Jeong and Yoon, Seug Yun and Kim, Kyoung Ha and Lee, Namsu and Park, Rojin and Park, Seong Kyu and Won, Jong-Ho},
title = {Src Family Kinase Inhibitors Bosutinib and Dasatinib Enhance ATRA-induced Differentiation of NB4 Leukemia Cells},
journal = {Anticancer Research},
year = {2026},
volume = {46},
number = {7},
pages = {3831--3844},
doi = {10.21873/anticanres.18244}
}
EUVIMED